{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1380016870447765397.json","@type":"Researcher","foaf:Person":[{"foaf:name":[{"@value":"Shiho Yamamoto"}],"foaf:familyName":[{"@value":"Yamamoto"}],"foaf:givenName":[{"@value":"Shiho"}]}],"career":[{"institution":{"notation":[{"@value":"Shionogi Pharmaceutical Research Center, 3-1-1 Futaba-cho, Toyonaka, Osaka 561-0825, Japan"}]}}],"product":[{"@id":"https://cir.nii.ac.jp/crid/1360016870447765376","@type":"Article","productIdentifier":[{"@type":"DOI","@value":"10.1021/acs.jmedchem.2c00117"},{"@type":"URI","@value":"https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.2c00117"},{"@type":"DOI","@value":"10.1101/2022.01.26.477782"},{"@type":"PMID","@value":"35352927"}],"notation":[{"@value":"Discovery of S-217622, a Noncovalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19"}],"relation":[{"type":"creator"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1021/acs.jmedchem.2c00117_JIxCDVYt88MyFXIE28QgWbDb5Qr"},{"@type":"OPENAIRE","@value":"doi_dedup___::cda3f19d8c44fa9a7e86dcee58fa2330_JIxCDVYt88MyFXIE28QgWbDb5Qr"}]}